DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Mateo, Joaquı́n; Carreira, Suzanne; Sandhu, Shahneen; Miranda, Susana; Mossop, Helen; Pérez-López, Raquel; Nava Rodrigues, Daniel; R. Robinson, Dan; Omlin, Aurelius; Tunariu, Nina; Boysen, Gunther; Porta, Núria; Flohr, Penny; Gillman, Alexa; Figueiredo, Ines; Paulding, Claire; Seed, George; Jain, Suneil; Ralph, Christy; Protheroe, Andrew; A. Hussain, Syed; J. Jones, Robert; Elliott, Tony; McGovern, Ursula; Bianchini, Diletta; Goodall, Jane; Zafeiriou, Zafeiris; T. Williamson, Chris; Ferraldeschi, Roberta; Riisnaes, Ruth; Ebbs, Bernardette; Fowler, Gemma; Roda, Desamparados; Yuan, Wei; Wu, Yi‐Mi; Cao, Xuhong; Brough, Rachel; N. Pemberton, Helen; A’Hern, Roger; Swain, Amanda; P. Kunju, Lakshmi; A. Eeles, Rosalind; Attard, Gerhardt; J. Lord, Christopher; Ashworth, Alan; A. Rubin, Mark; E. Knudsen, Karen; Y. Feng, Felix; M. Chinnaiyan, Arul; Hall, Emma; S. de Bono, Johann

doi:10.1056/nejmoa1506859

Public

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Published in New England Journal of Medicine • Oct 28, 2015

Authors:

Joaquı́n Mateo

Suzanne Carreira

Shahneen Sandhu

Abstract

BACKGROUND: Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibit...

Subject

Olaparib

Poly ADP ribose polymerase

Prostate cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!